Ballarat Health Services, Victoria, Australia; Monash University, Victoria, Australia.
Flinders Medical Centre, South Australia, Australia.
Res Social Adm Pharm. 2023 Mar;19(3):432-444. doi: 10.1016/j.sapharm.2022.09.018. Epub 2022 Oct 11.
Pharmacists are involved in the care of patients with cardiac disease within the ambulatory setting across multiple modes of delivery and practice settings. There is a lack of consensus surrounding the assessments used to measure the impact of pharmacist care. This heterogeneity may undermine confidence and limit utilisation of pharmacists in cardiology ambulatory care. A systematic review was conducted to understand how pharmacist interventions in cardiology ambulatory care were assessed and the impacts of these interventions on patient-centred outcomes.
A comprehensive search was conducted of MEDLINE, CINAHL Plus, Cochrane Register of Randomised Controlled Trials and EMBASE from 2000 to 2020 with search terms involving pharmacist interventions among cardiology patients in the ambulatory care setting; with studies restricted to randomised controlled trials. Search results were independently screened by two reviewers. The Cochrane Risk of Bias in Randomised Trials tool was used for quality assessment of the included studies. Assessments of pharmacist impact were analysed and compared to established quality indicators of cardiology care. The search produced 3380 individual studies, following screening, 26 studies involving 9013 participants met inclusion criteria. Across the 26 included studies, eleven different intervention types were identified. Four main outcome measures assessing the impact of these interventions were identified: direct measure of cardiovascular disease risk factor, major adverse cardiovascular events, medication adherence, validated risk score for cardiovascular events. There was a high degree of variance in both the way these interventions influenced the outcome as well the outcome measures selected to assess the impact of the intervention. Of the 26 studies, sixteen listed positive impacts on primary outcomes and the remaining 10 listed neutral effects.
Several outcome measures have been used to assess the impact of pharmacist intervention in cardiology ambulatory care. Aligning outcome measures with known indicators of cardiology care quality, as well as more detailed descriptions of intervention, will provide clinicians vital information in designing effective and measurable interventions in cardiology ambulatory care.
药剂师在多种提供方式和实践环境中参与门诊心脏病患者的护理。用于衡量药师护理影响的评估方法缺乏共识。这种异质性可能会降低信心,并限制药师在心血管门诊护理中的应用。进行了系统评价,以了解心血管门诊护理中药师干预措施的评估方法以及这些干预措施对以患者为中心的结果的影响。
对 2000 年至 2020 年间 MEDLINE、CINAHL Plus、Cochrane 随机对照试验登记处和 EMBASE 进行了全面检索,检索词涉及心血管病患者在门诊环境中的药师干预措施;研究仅限于随机对照试验。由两名评审员独立筛选检索结果。采用 Cochrane 随机对照试验偏倚风险工具对纳入研究进行质量评估。分析和比较了药师影响评估与心血管护理的既定质量指标。搜索产生了 3380 项单独的研究,经过筛选,有 26 项研究涉及 9013 名参与者符合纳入标准。在 26 项纳入的研究中,确定了 11 种不同的干预类型。确定了评估这些干预措施影响的四个主要结果测量指标:心血管疾病危险因素的直接测量、主要不良心血管事件、药物依从性、心血管事件的验证风险评分。这些干预措施对结果的影响以及用于评估干预效果的结果测量指标在很大程度上存在差异。在 26 项研究中,有 16 项列出了对主要结果的积极影响,其余 10 项列出了中性影响。
已经使用了几种结果测量指标来评估心血管门诊护理中药师干预的影响。将结果测量指标与心血管护理质量的已知指标以及干预措施的更详细描述相匹配,将为临床医生在设计心血管门诊护理中的有效和可衡量的干预措施方面提供重要信息。